

CheckedUp Technologies Help Notal Vision Expand Age-Related Macular Degeneration Patient Awareness

Platform uses groundbreaking technologies to increase patient awareness of ForeseeHome AMD Monitoring Program for early detection of leading cause of irreversible blindness in the US

NEW YORK, N.Y., July 19, 2018 - CheckedUp, a specialty point of care company, announced today a collaboration with Notal Vision, a privately-held ophthalmic company and providers of the ForeseeHome ™ Monitoring Program for Wet Age-Related Macular Degeneration (AMD) detection. ForeseeHome is a cloud-based patient-activated platform for home diagnostic testing. The joint effort will focus on using CheckedUp's nationwide network in eye care provider's waiting and consultation rooms to deliver educational content about the importance of catching the conversion from dry to wet AMD as early as possible and patients retain good, functional vision.

"A patient with AMD requires significant attention to ensure that their progression from dry to wet AMD is noticed and addressed. As an in-office platform dedicated to improving the patient experience and empowering patients in the diagnosis and treatment of their specific disease, we are well suited to help address this need," said Eugene deJuan Jr, MD, USCF title, who is a member of the Board of Directors of CheckedUp. "Our collaboration with Notal Vision brings two technologies together, within practices that prescribe the ForeseeHome program, to encourage early detection and diagnosis, allowing both physicians and patients to benefit from this advanced, in-home test to obtain optimal vision outcomes. We look forward to having Checkedup's reach spread awareness of this new technology to help AMD patients preserve their vision."

CheckedUp's specialty point of care platform includes technologies such as Explorer Waiting Room TV, which builds awareness and provides education to patients as they wait for their appointment. It also includes the Consult Digital Exam Room Wallboard, which improves the patient-physician dialogue and productivity by quickly and easily presenting conditions and educational content. Physicians can zoom, rotate and annotate on 3D anatomical rendering and share them with their patients via email. Through these platforms, dry AMD patients will be able to learn more about their disease, the ForeseeHome Program, and the benefit of home-based testing between their routine eye exams.

The ForeseeHome program allows patients with dry AMD to test their vision from the comfort of their own home, providing physicians with the ability to monitor their patients between office visits. The cloud-based analysis of patients' daily testing data is conducted by the Notal Vision Diagnostic Clinic and shared with prescribing doctors. In addition, significant changes in vision are identified and a report sent to the prescribing physician enabling timely assessment of the patient. The FDA cleared and Medicare reimbursed ForeseeHome AMD Monitoring Program is available to patients with a prescription from their eye doctor.

"The clinical data speaks for itself – ForeseeHome addresses a large unmet need, benefiting both doctors and patients," said Quinton Oswald, CEO of Notal Vision. "Notal Vision seeks to provide patients who are at risk for the sudden, and vision robbing, progression from dry to wet AMD with disease awareness and an understanding of the role they can play in preserving their own good vision. By adding the CheckedUp platform to our ForeseeHome educational initiatives, we are confident that we will elevate patient awareness on the risk of progressing to wet AMD and the benefit of earlier detection."

About CheckedUp

CheckedUp is the premier specialty technology platform at the point of care actively engaging patients and physicians in the waiting room, exam room and at home. As a health technology leader, CheckedUp aspires to create better educated and more confident patients and physicians who are empowered to make informed health decisions together. Learn more at www.CheckedUp.com

About Notal Vision, Ltd.

Notal Vision was founded by two ophthalmologists and is committed to providing the eyecare community with innovative, home-based, diagnostic technologies that support visual health in patients with retinal diseases. ForeseeHome is the first FDA-cleared remote diagnostic testing device that detects and characterizes visual distortion in AMD patients as an aid to monitoring choroidal neovascularization progression. To learn more, visit <u>www.notalvision.com</u>.